peptide guide FAQ

If the vial was at room temperature (18–22°C) for 8–12 hours, expect 5–15% potency reduction. The peptide is not completely ruined, but you've shortened its viable use window. Refrigerate it immediately and use it within 14 days instead of the standard 28. Do not attempt to 'restore' potency by lowering the temperature; cold storage only slows further degradation. It does not reverse damage already incurred. If the ambient temperature exceeded 25°C (common in summer), discard the vial. The cost of continuing with degraded peptide exceeds the cost of replacement when research outcomes depend on consistent dosing.

Use the same formula regardless of vial size: peptide mass (mg) ÷ diluent volume (mL) = concentration (mg/mL). For a 3mg vial reconstituted with 1.5mL bacteriostatic water: 3mg ÷ 1.5mL = 2mg/mL (2000mcg/mL). A 400mcg dose requires 400mcg ÷ 2000mcg/mL = 0.2mL. The principle doesn't change. Only the input numbers do. Verify your syringe can measure the resulting injection volume with adequate precision before finalizing your reconstitution volume choice.

Metabolic adaptation is expected. Basal metabolic rate decreases 8–12% during sustained deficit as thyroid output (T3 conversion) downregulates and non-exercise activity thermogenesis (NEAT) drops by 200–400 calories daily. Two options: (1) accept slower fat loss for the final two weeks and maintain current deficit without further restriction, or (2) implement one refeed day at maintenance calories (typically adding 400–600 calories from carbohydrates) to temporarily upregulate leptin and improve training performance. The refeed option delays beach readiness by 2–3 days but improves final-week adherence and prevents post-protocol rebound.

Bodyweight training maintains mechanical tension sufficiently for 1–2 weeks. Focus on tempo work (3–4 second eccentrics) and volume (15–20 reps per set) to compensate for reduced load. The peptide continues suppressing appetite during travel, which is the higher-value variable. Fat loss progression slows by approximately 15–20% during travel weeks due to reduced training stimulus, but muscle catabolism remains minimal if protein intake stays at 1.6g per kilogram daily minimum. Resume resistance training immediately upon return. Strength may drop 5–10% temporarily but recovers within one week.

Four weeks allows approximately 3–4% body fat reduction under optimal conditions. Visible but not dramatic. Start at week-1 dosing (2.5mg tirzepatide or 0.25mg semaglutide) immediately rather than titrating, accept higher nausea risk, and increase training frequency to 5–6 sessions weekly. The compressed timeline eliminates margin for error. One week of poor adherence cuts total fat loss by 25–30%. Realistic expectation: you'll look leaner than you do now, but not beach-cover-shoot ready unless starting body composition is already low.

Reduce peptide dose by 50% for one week while maintaining training schedule and protein intake. Nausea that disrupts training is counterproductive. The peptide's value is adherence support, not forced deficit through illness. Once GI symptoms resolve (typically 5–7 days), resume the original dose or titrate more slowly. Missing one week of full-dose therapy costs approximately 0.5–0.75% body fat reduction over 8 weeks, but missing training volume costs 2–3× that amount in muscle retention.

SS-31's protective effects are dose-dependent and time-sensitive. Missing one pre-workout dose means you lose the acute mitochondrial stabilization for that session but doesn't negate prior or future administrations. Unlike chronic adaptogenic compounds where missing a dose disrupts cumulative buildup, SS-31 for exercise performance acts acutely: each dose protects mitochondria during the oxidative stress window 1–4 hours post-injection. If you miss the pre-workout window, you can still administer post-workout within 30 minutes to target recovery rather than performance. Studies show significant reductions in muscle damage markers and faster return to baseline power output when SS-31 is given immediately after intense training.

Administer SS-31 for exercise performance 60–90 minutes before efforts exceeding 90 minutes, when mitochondrial oxidative stress peaks and ATP synthesis efficiency declines. The 'wall' in ultra-endurance isn't purely glycogen depletion. It's mitochondrial membrane deterioration under sustained ROS production. Research in competitive cyclists showed SS-31 delayed the point of power output decline by 18% of total ride duration (from 28 km to 33 km in a 40 km time trial). You'll still need substrate availability (carbohydrates, electrolytes), but SS-31 keeps the mitochondria processing that substrate efficiently rather than degrading under oxidative load. Chronic daily dosing for 4–6 weeks before a key event may provide additional adaptation through improved mitochondrial biogenesis markers.

Verify peptide purity and reconstitution protocol first. Degraded or improperly stored SS-31 loses mitochondrial targeting efficiency. SS-31 for exercise performance requires ≥98% purity to maintain consistent cardiolipin binding. If reconstituted peptide is stored above 8°C or exposed to repeated temperature fluctuations, the tetrapeptide structure degrades and mitochondrial uptake declines. Second, assess whether recovery limitations are mitochondrial or systemic: inadequate sleep, chronic caloric deficit, or elevated cortisol from overtraining will blunt recovery regardless of mitochondrial health. SS-31 protects mitochondria from oxidative damage. It doesn't override systemic recovery debt. If purity and storage are verified and systemic factors are controlled, consider increasing dose from 1 mg/kg to 1.5–2 mg/kg or extending dosing frequency to daily rather than training-day-only.

SS-31 for exercise performance stacks mechanistically well with peptides that enhance growth hormone signaling or metabolic flexibility, such as Ipamorelin or MOTS-c, because they operate through different pathways. SS-31 protects existing mitochondrial function, while growth hormone peptides promote mitochondrial biogenesis and muscle protein synthesis over weeks. There's no receptor competition or overlapping metabolic burden. One common pairing in research contexts: SS-31 administered pre-workout for acute performance and recovery protection, with Ipamorelin administered before sleep to support overnight anabolic processes. The two complement rather than interfere. SS-31 keeps current mitochondria healthy, while GH secretagogues build more of them.

Contact the supplier immediately and request a replacement. Lyophilised peptides can tolerate short-term ambient temperature exposure better than reconstituted solutions, but shipping without cold chain protocols violates industry standards for peptide handling. If the package was in transit for more than 72 hours without temperature control, or if you're in a region with summer temperatures exceeding 30°C, the peptide has likely experienced significant degradation. Reputable suppliers like Real Peptides include cold packs and temperature monitoring in every shipment precisely to prevent this scenario. Do not assume the peptide is viable based on appearance. Demand proof of cold chain compliance or a replacement vial.

Use a medical-grade cooler with gel packs pre-frozen to −20°C and transport within a 6-hour window. For reconstituted TB-4, place the vial in a secondary containment bag (to prevent leakage if the seal fails) and surround it with frozen gel packs. Aim to maintain 2–8°C throughout transit. For lyophilised vials, the same cold chain approach applies but with slightly more tolerance for brief temperature fluctuations. Never transport peptides in a standard insulated lunch bag without verified temperature monitoring. These rarely maintain stable temperatures beyond 2–3 hours. If transport will exceed 6 hours, use a portable medical refrigerator with active temperature control.

Assume 20–30% potency loss and do not refreeze it. Use the vial within the next 7 days and prioritise it for non-critical applications or preliminary dose-response testing. Freezing reconstituted peptides causes ice crystal formation that disrupts molecular structure. This is not the same as controlled lyophilisation, which is performed under vacuum with cryoprotectants. The damage is done, but the peptide isn't entirely useless. What you must not do is treat it as fully potent or subject it to additional freeze-thaw cycles, which would compound the degradation exponentially.

Refrigerate it immediately and use it within the next 7 days instead of the full 28-day window. Four hours at room temperature (20–25°C) will cause partial but not total denaturation. Expect approximately 10–15% potency loss based on thermal degradation kinetics. The solution will still appear normal, so you cannot assess damage visually. If the ambient temperature was higher than 25°C (summer room temperature, car interior), assume 20–25% loss and adjust your protocol timeline accordingly. Document the incident and avoid using that vial for critical early-stage experiments where consistency is paramount.

If the lyophilised vial feels warm to the touch upon delivery, check the shipping timeline. Lyophilised peptides can tolerate ambient temperature (15–25°C) for 48–72 hours without significant degradation. The absence of water in the lyophilised state prevents hydrolytic breakdown even at room temperature. If shipping took longer than 72 hours, contact the supplier for a replacement. At Real Peptides, we ship with cold packs for this exact reason, but delays beyond carrier control do happen.

That's acceptable for lyophilised storage but not ideal. Minor fluctuations within the subzero range don't introduce enough thermal energy to denature the peptide in its freeze-dried state. The bigger risk is condensation. If the vial warms enough for moisture to condense on the stopper, that water vapor can rehydrate the powder. Store the vial in a sealed plastic bag to create a moisture barrier, and check the powder visually before reconstitution. If it looks clumpy or discolored instead of fine and white, moisture has infiltrated.

Use a portable medical cooler designed for insulin or peptide transport. Brands like FRIO or MedActiv maintain 2–8°C for 24–48 hours using evaporative cooling without requiring ice or refrigeration. Pack the vial upright, cushioned to prevent physical agitation during transport. Avoid gel ice packs placed directly against the vial. They can freeze the solution if they're too cold. If transport time exceeds 48 hours, reconstitute a fresh vial at the destination site rather than risking temperature excursions mid-transit.

Check the actual temperature the vials reached using a freezer thermometer if available. If the internal temperature stayed below 0°C, the lyophilised peptide is fine. No action needed. If it rose above 0°C but stayed below 15°C for fewer than 12 hours, expect minor potency loss (5–10%) but the vial remains usable. If the temperature exceeded 15°C or stayed warm for more than 24 hours, treat this as a compromised batch. The peptide won't look different, but the tertiary structure may have partially unfolded, reducing receptor-binding efficacy.

Split the lyophilised powder into smaller aliquots before the 24-month mark. Reconstitute one aliquot at a time so you're not repeatedly thawing and refreezing a single large batch. Each freeze-thaw cycle introduces moisture and accelerates degradation. If you must store beyond two years, keep the vial at −80°C (ultralow freezer) instead of −20°C. Peptide stability extends to 36–48 months at ultralow temperatures, though few labs have routine access to −80°C storage.

Discard the vial and start fresh. A reconstituted peptide left at room temperature (20–25°C) for 8–12 hours has likely lost 30–50% of its potency through accelerated hydrolysis and thermal denaturation. You can't visually confirm potency loss. The solution will still look clear and normal. But the biological activity is compromised. The cost of replacing the vial is far lower than the risk of using a degraded compound in research where dose accuracy matters.